Abstract 4522: Potent induction of a tumor-specific immune response by a cyclic dinucleotide STING agonist
Gabriela Gremel(Boehringer Ingelheim (Austria)), Norbert Kraut(Boehringer Ingelheim (Austria)), Martin Fleck(Asklepios Kliniken Bad Abbach), Ute Klinkhardt(Boehringer Ingelheim (Germany)), Vittoria Zinzalla(Boehringer Ingelheim (Austria)), Thorsten Oost(Abbott (United States)), Sophia M. Blake(Boehringer Ingelheim (Austria)), Achim Grube(Boehringer Ingelheim (Germany)), Georg Rast(WWF Germany), Maria Antonietta Impagnatiello(Boehringer Ingelheim (Austria)), Marco H. Hofmann(Boehringer Ingelheim (Austria)), Herbert Nar(Boehringer Ingelheim (Germany)), Kirsten Arndt-Schmitz(Boehringer Ingelheim (Germany)), Thomas Zichner(German Cancer Research Center), Paolo Chetta(Boehringer Ingelheim (Austria)), Otmar Schaaf(Boehringer Ingelheim (Austria)), Sebastian Carotta(Boehringer Ingelheim (Austria)), Esther Schmidt(European Bioinformatics Institute), Thorsten Laux(Boehringer Ingelheim (Germany)), Jonathon D. Sedgwick(Cellular Research (United States)), Tom Bretschneider(Boehringer Ingelheim (Germany))
Cited by 5
Related Papers
Patterns of somatic mutation in human cancer genomes
|Nature|2007|3.1k
The whole-genome landscape of medulloblastoma subtypes
|Nature|2017|1.2k